Cedar was commissioned by NICE to determine the incidence of hypoglycaemic episodes in type 1 diabetes, and the impact of these episodes on healthcare resource use. This project also aimed to determine whether the fear of a hypoglycaemic episode impacts upon the individual’s quality of life. The project used linked healthcare records obtained from the SAIL databank in order to determine the number of hypoglycaemic episodes in patients with type 1 diabetes. These data were combined with type 1 registration data from the National Diabetes Audit in order to determine the cumulative incidence of hypoglycaemia in type 1 diabetes. This work may be used in the future to inform a review of NICE diagnostic guidance on Integrated sensor-augmented pump therapy systems for managing blood glucose levels (DG21).
Cedar’s report from the HERO study can be found HERE.